Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares OutstandingShares OutstandingShares Repurchased
Ratios

Actinium Pharmaceuticals (ATNM) Receivables - Other (2021 - 2023)

Actinium Pharmaceuticals (ATNM) has disclosed Receivables - Other for 4 consecutive years, with $307000.0 as the latest value for Q2 2023.

  • Quarterly Receivables - Other fell 21.68% to $307000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $307000.0 through Jun 2023, down 21.68% year-over-year, with the annual reading at $302000.0 for FY2022, 22.96% down from the prior year.
  • Receivables - Other for Q2 2023 was $307000.0 at Actinium Pharmaceuticals, up from $304000.0 in the prior quarter.
  • The five-year high for Receivables - Other was $392000.0 in Q1 2021, with the low at $300000.0 in Q3 2022.
  • Average Receivables - Other over 3 years is $356500.0, with a median of $392000.0 recorded in 2021.
  • Peak annual rise in Receivables - Other hit 0.0% in 2022, while the deepest fall reached 23.47% in 2022.
  • Over 3 years, Receivables - Other stood at $392000.0 in 2021, then decreased by 22.96% to $302000.0 in 2022, then rose by 1.66% to $307000.0 in 2023.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $307000.0, $304000.0, and $302000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.